Sanofi’s shift to immunology, AI-driven R&D, and strong pipeline offset risks from patent cliffs and legal issues. See why ...

Sanofi has finalized its takeover of Vigil Neuroscience for roughly $470 million, acquiring all outstanding shares at $8 each and issuing a $2-pe ...

Sanofi’s commitment to sustainability has been recognized globally, with TIME ranking it as the world’s 10th most sustainable company across all industries and #1 in pharma and biotech. This accolade ...

Sanofi Q2 sales rose 10.1% at constant currency, led by Dupixent and ALTUVIIIO. EPS missed estimates; 2025 sales guidance was ...

Investing.com -- Sanofi (EPA: SASY) shares fell more than 2% on Thursday after the pharmaceutical and healthcare company ...

AstraZeneca ’s AZN second-quarter 2025 core earnings of $1.09 per American depositary share (ADS) came in line with the Zacks ...

"These results support BEYFORTUS as a groundbreaking advancement in infant RSV disease prevention. With more than 40 real-world evidence studies to date, this latest study further strengthens the ...

87% reduction in cases of respiratory syncytial virus (RSV) disease across all sites of care among healthy, term babies, born ahead of or during the RSV season98% reduction in hospitalizations of ...

BEYFORTUS® reduced hospital and doctor visits for RSV disease in babies by 87%, according to largest US real-world study ...

Sanofi agreed to buy UK biotech Vicebio Ltd. for as much as $1.6 billion, gaining experimental vaccines and a technology to streamline their development. The French drugmaker will pay $1.15 billion ...